Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B – follow-up from the RETRACT-B cohort

Journal of Hepatology 2026 Open access

Read full text
Authors: Edo J. Dongelmans, Grishma Hirode, Florian van Bӧmmel, Wen-Juei Jeng, Rong-Nan Chien, Chien-Hung Chen, Mai Kilany, Ta‐Chen Su, J. Tze-Wah Kao, Wai-Kay Seto, Lilian Yan Liang, Dag Henrik Reikvam
+22 more Marte Holmberg, Arno Furquim d'Almeida, Μargarita Papatheodoridi, Benjamin Maasoumy, Bettina Hansen, Richard Post, Anna Pocurull, Norah Terrault, Marc Ghany, Asgeir Johannessen, Anna Lok, Thomas Vanwolleghem, Sabela Lens, Markus Cornberg, Man-Fung Yuen, Grace Wong, Milan J. Sonneveld, George Papatheodoridis, T. Berg, Yao‐Chun Hsu, Jordan Feld, Harry Janssen
DOI: 10.1016/j.jhep.2026.03.030
Cited by: 6
References: 51

Abstract

BACKGROUND & AIMS: Stopping nucleos(t)ide analogues (NAs) in patients with chronic hepatitis B can increase hepatitis B surface antigen (HBsAg) loss rates. However, long-term follow-up (FU) data after NA cessation in a multiethnic population are lacking. This study aimed to assess long-term outcomes after NA cessation in a large global cohort. METHODS: Extended FU data were collected from patients enrolled in the RETRACT-B cohort. New patients were added if they met the inclusion criteria (virally suppressed, HBeAg negative, and HBsAg positive at end of therapy [EOT]). The primary outcome was the 10-year off-treatment HBsAg loss rate. Secondary outcomes were retreatment and adverse events. RESULTS: IU/ml (

Fields of Study & Subjects

Hepatitis B Virus Studies Hepatitis C virus research Liver Diseases and Immunity

Publication details

Journal / source
Journal of Hepatology
Publisher
Elsevier BV
Volume
85
Issue
1
Pages
61–70
Publication date
30 March 2026
Language
EN